Clinical trial
Glucocorticoid Effects in Patients With DM Type 2
Name
16-035
Description
Participants will receive prednisone 40 mg for 3 days. 75 g oral glucose tolerance test (OGTT), insulin and C-peptide will be measured on day 1 (before prednisone) and day 3 (after prednisone). Also capillary glucose values will be obtained during and after the period of prednisone intake.
Trial arms
Trial start
2016-06-03
Estimated PCD
2017-04-01
Trial end
2017-07-01
Status
Completed
Phase
Early phase I
Treatment
Prednisone
40 mg po q day of Prednisone for 3 days
Arms:
Prednisone in control subjects, Prednisone in subjects with Diabetes
Other names:
Deltasone, Prednicot, Rayos
Size
10
Primary endpoint
AUC for glucose during OGTT
Throughout the course of 3 days
Eligibility criteria
Experimental Group
Inclusion Criteria:
1. Males or non-pregnant females between the ages of 18-50 years being followed in the Diabetes Center.
2. Type 2 Diabetes for ≤ 1 year and only on metformin
3. BMI 24.0-35.0 kg/ m2
4. HBA1c ≤ 9.0%
Exclusion Criteria:
1. Patients on any other antidiabetes medication.
2. Patients with impaired renal function (estimated Glomerular Filtration Rate (GFR) less than 60 ml/min based on results from Cerner).
3. Patient who have received glucocorticoid therapy within six months of study.
4. Patients who do shift work.
5. Blood glucose level ≥ 250 mg/dl on finger-stick at clinic visit.
6. Signs or symptoms of infection.
Control Group
Inclusion Criteria:
1. Males or non-pregnant females between the ages of 18-50 years in good physical health as determined by medical history, physical examination, and screening blood tests
2. Normoglycemia defined by fasting plasma glucose \< 5.6 mmol/L (or 100 mg/dL) and 2h glucose \<7.8 mmol/L (or 140 mg/dL) after a 75 g OGTT
3. BMI: 22.0 - 28.0 kg/m2
Exclusion Criteria:
1. Presence of any disease or use of any medication
2. Patients with a first-degree relative with Type 2 Diabetes
3. Patients who smoke
4. Patients with history of steroid use in previous 6 months.
5. Patients who do shift work
6. Signs or symptoms of infection.
7. Patients with recent changes in weight or physical activity
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Two groups. Condition group and Control group, both receiving the investigated medication using the same protocol', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ACTUAL'}}
Updated at
2023-09-26
1 organization
1 product
2 indications
Organization
Cook County HealthProduct
PrednisoneIndication
DiabetesIndication
Hyperglycemia